The United States has approved the use of Pretomanid Tablets to treat an extremely drug-resistant strain of tuberculosis.
Pretomanid when used in combination with antibiotics bedaquiline and linezolid cured 89% of 107 patients with extensively drug-resistant TB after 6 months.
The above three drugs together called BPaL regimen.
Because of the new treatment, TB patients who were supposed to take 30 pills a day can now take only 5 pills a day.